Combination with
DCprime
Kempen & Co is pleased to announce that it acted as Financial Advisor in the combination between DCprime and Immunicum.
Transaction highlights
- Kempen & Co has advised DCprime on its business combination with Immunicum, a Swedish-listed biopharmaceutical company. Immunicum will acquire all of the outstanding shares in DCprime for SEK 599 million, paid by an issue in kind of Immunicum shares
- The deal combines two synergistic therapeutic approaches and establishes a leader in cell-based cancer immunotherapeutics, with a diversified pipeline containing multiple clinical assets in both blood-borne and solid tumours
- The combination was supported by the majority shareholders of both companies, Van Herk Investments and AP4 fonden. Van Herk Investments, a leading European life science investor, holds c. 43% of the shares in the combined entity
- Following the combination, Van Herk Investments intends to invest up to SEK 82.5 million in the combined entity
- This transaction concludes a very successful year for Kempen & Co, acting as our third successful Life Sciences M&A deal in 2020, and our first involving a Scandinavian company, further expanding our offering in the region
Company description
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. DCprime’s lead product, DCP-001, is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse, currently in Phase II trials in AML. DCprime is pursuing similar vaccination approaches for solid tumors. DCprime believes relapse vaccines will improve survival by putting the patient’s immune system back in control.
Following the combination, DCprime will become part of Immunicum. The combined entity will trade on the Nasdaq Stockholm exchange (STO: IMMU).
Background Kempen & Co Life Sciences & Healthcare
In 2020, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
- Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
- Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
- Lead Manager in the USD 85.0 million Nasdaq Initial Public Offering by Galecto
- Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
- Bookrunner in the USD 245 million Nasdaq Initial Public Offering by Curevac
- Co-Manager in the USD 49.0 million US Public Offering by Centogene
- Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
- Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
- Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
- Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp., thereby becoming a Nasdaq listed company and securing USD 253 million
- Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
- Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
- Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
- Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
- Co-Manager in the USD 862 million Global Offering by argenx
- Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides
- Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
- Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical
Contact


Read more on:
Transactions
No transactions found
Sale to
Combination with
Accelerated Bookbuild Offering
Sale to
Accelerated Bookbuild Offering
Non-listed equity capital raising
Sale of majority stake to
Secondary Sell-Down in Calliditas Therapeutics
Capital increase
Initial Public Offering
Capital Increase
European FinTech
IPO
Accelerated Bookbuild Offering
Private Placement of shares in
Bridge financing
Undisclosed
Initial Public Offering
Rights issue
Accelerated Bookbuild Offering
US Public Offering
Accelerated Bookbuild Offering
US Public Offering
Merger with Arya Sciences Acquisition Corp. and subsequent Nasdaq listing
acquisition of
Initial Public Offering
Private Placement
Private Placement
Accelerated Bookbuild Offering
Global Accelerated Bookbuild Offering
Accelerated bookbuild offering
Sale of 456 unit landmark residential project in prime location The Hague
acquired by
public offer for
Sale and capital increase
and
Sale of Dutch residential development to
Global Offering
Accelerated Bookbuild Offering
Public takeover of
Private placement of shares
Series C Capital increase
Rights issue
Placement of treasury shares
Public takeover financing
Sale of
to
Accelerated Bookbuild Offering
Capital increase
Global offering
Rights issue
US public offering
Initial Public Offering
Accelerated bookbuild offering
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Acquisition of
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Increase of stake in
Initial Public Offering
Acquisition of
Acquisition of
Acquisition of
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio
to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Series B Capital increase
Public offer for
Global offering
Accelerated bookbuild offering
Fundraise
Accelerated bookbuild offering
Public offer by German ADLER Real Estate
for Israeli
Public offer by German Vonovia
for German-Austrian Buwog
Rights issue
Accelerated bookbuild offering
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Accelerated bookbuild offering
Sale of 3 German residential portfolios by
to consortium of buyers
Accelerated bookbuild offering
US public offering
Accelerated bookbuild offering
Secondary offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Secondary offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Inaugural bond issue
Acquisition by
of
from
Initial public offering
Accelerated bookbuild offering
Initial public offering on NASDAQ
Capital raise
Share buy-back program
Share buy-back program
Capital raise
Acquisition by
of
Accelerated bookbuild offering
Capital increase with priority allocation rights
Rights issue
Secondary placement of 9.4% stake in
Public offer by
for
Public offer by German Vonovia
For Austrian Conwert
Secondary placement of 15% stake in
Formation of Passoã joint venture with
Accelerated bookbuild offering
Rights issue
Capital increase with priority allocation rights
Sale of 19% stake in
Accelerated bookbuild offering
Accelerated bookbuild offering
Capital increase with priority allocation rights
Rights issue
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Initial public offering
Accelerated bookbuild offering
Private placement
Strategic study
Placement of treasury shares
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Management participation advisory in dual-track sale process
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco

Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Initial Public Offering
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Rights issue